Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish "MALOVA" ovarian cancer study

Cancer

Volumn 98, Issue 1, 2003, Pages 66-73

  Høgdall, Estrid V S ^a,b   Christensen, Lise ^c   Kjaer, Susanne K ^a   Blaakaer, Jan ^d   Bock, Johannes E ^c   Glud, Eva ^a   Nørgaard Pedersen, Bent ^b   Høgdall, Claus K ^c  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

HER 2; Immunohistochemistry; Ovarian carcinoma; Survival

Indexed keywords

CA 125 ANTIGEN; TETRANECTIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 0038340769     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11476     Document Type: Article

References (36)

1. Kjæer S, Ewertz M. Ovarian cancer in Denmark 1943-1982: kræftstatistik nr. 20. Ugeskr Lœger. 1987;149:3356-3360.
2. Kjaer SK, Storm HH. Female genital organs. In: Carstensen B, Storm HH, Schou G, editors. Survival of Danish cancer patients 1943-87. Supplement 33. Copenhagen: APMIS, Munksgaard, 1993:107-121.
3. Gøtrik JK, Hjulsager M. Cancer incidence in Denmark. Copenhagen: Sundhedsstyrrelsen, 1997:1-81.
4. Association of the Nordic Cancer Registries (ANCR). Cancer in the Nordic countries. Copenhagen: Association of the Nordic Cancer Registries, 1999:1-19.
5. Weinberg RA. How cancer arises. Sci Am. 1996;275:32-40.
6. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993;53:891-898.
7. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001;61:2420-2423.
8. McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 1993;71:3942-3946.
9. Berchuck A. Biomarkers in the ovary. J Cell Biochem Suppl. 1995;23:223-226.
10. Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig. 1996;3:99-105.
11. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 1993;168:162-169.
12. Hogdall CK, Mogensen O, Tabor A, et al. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol. 1995;56:22-28.
13. Möbus V, Kreienberg R, Crombach G, et al. Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol. 1988;3:251-258.
14. Makar AP. Prognostic studies in cancer of the ovary and Fallopian tube with emphasis on the CA 125 antigen and c-erbB-2 oncogene. Acta Obstet Gynecol Scand. 1995;74:238-240.
15. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992;79:1002-1010.
16. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
17. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996;313:1355-1358.
18. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-1538.
19. Åstedt B, Svanberg L, Nilsson IM. Fibrin degration products and ovarian tumors. BMJ. 1971;4:458-459.
20. Peterson HI, Kjartansson I, Korsan-Bengtsen K, Rudenstam CM, Zettergren L. Fibrinolysis in human malignant tumors. Acta Chir Scand. 1973;139:219-223.
21. Malone JM, Wangensteen SL, Moore WS, Keown K. The fibrinolytic system: a key to tumor metastasis. Ann Surg. 1979;190:342-348.
22. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
23. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 1992;18:104-116.
24. Høgdall EV, Høgdall CK, Tingulstad S, et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer. 2000;89:519-523.
25. Høgdall CK, Høgdall EVS, Hørding U, et al. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol. 1991;43:103-107.
26. Jensen BA, Clemmensen I. Plasma tetranectin is reduced in cancer and related to metastasia. Cancer. 1988;62:869-872.
27. Høgdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer. 1993;72:2415-2422.
28. Høgdall CK, Høgdall EVS, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest. 1993;53:741-746.
29. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92:2965-2974.
30. Jensen BA, McNair P, Hyldstrup L, Clemmensen I. Plasma tetranectin in healthy male and female individuals, measured by enzyme-linked immunosorbent assay. J Lab Clin Med. 1987;110:612-617.
31. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
32. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer. 1994;73:1456-1459.
33. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer. 1995;72:521-527.
34. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087-4091.
35. Haldane JS, Hird V, Hughes CM, Gullick WJ. c-erbB-2 oncogene expression in ovarian cancer. J Pathol. 1990;162:231-237.
36. Buller RE, Anderson B, Connor JP, Robinson R. Familial ovarian cancer. Gynecol Oncol. 1993;51:160-166.